Impurity Profiling of Lumefantrine
Author Information
Author(s): Mathieu Verbeken, Suleman Sultan, Bram Baert, Elien Vangheluwe, Sylvia Van Dorpe, Christian Burvenich, Luc Duchateau, Frans H Jansen, Bart De Spiegeleer
Primary Institution: Ghent University
Hypothesis
The study aims to establish a comprehensive impurity profile of the anti-malarial drug lumefantrine.
Conclusion
The study identified nine lumefantrine-related impurities, including a new specified degradation impurity, DBK, which has a toxicity risk comparable to lumefantrine itself.
Supporting Evidence
- Nine lumefantrine-related impurities were detected and characterized.
- One new compound, DBK, was identified as a specified degradation impurity.
- The toxicity risk of DBK is comparable to that of lumefantrine.
Takeaway
Researchers looked at the impurities in a malaria drug called lumefantrine and found some new ones that could be harmful, just like the drug itself.
Methodology
The study used HPLC-DAD/UV-ESI/ion trap/MS to analyze market samples and stability results for impurity profiling.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website